The Food and Drug Administration does not intend to object to a manufacturer or authorized distributor delivering prescription drug samples directly to licensed practitioners or their patients at their homes during the COVID-19 emergency when requested by the practitioner in accordance with requirements, according to released yesterday.

FDA also does not intend to take action during the emergency against a manufacturer or authorized distributor that accepts alternatives to a signature to verify delivery and receipt of drug samples if the receipt complies with other requirements, the guidance states.

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…